Aipu Regenerative Medicine

Aipu Regenerative Medicine is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of human embryonic stem cell (hESC)-derived therapies for neurodegenerative and ophthalmic diseases. Founded by Dr. Su-Chun Zhang, a world-renowned expert in stem cell biology, the company leverages a proprietary differentiation platform to produce high-purity, functional cells for regenerative medicine. Its lead candidate, AP-001, is a dopaminergic neuron replacement therapy currently in Phase 1/2 clinical trials for Parkinson's disease, aiming to restore motor function by replacing lost neurons. Aipu's pipeline also includes programs for spinal cord injury and dry age-related macular degeneration, supported by advanced GMP manufacturing capabilities and partnerships with leading academic institutions.